SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Flanigan RC, Campbell SC, Clark JI, et al. Metastatic renal cell carcinoma. Curr Treat Options Oncol. 2003; 4: 385390.
  • 2
    Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000; 163: 408417.
  • 3
    Samuels BL, Hollis DR, Rosner GL, et al. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a Cancer and Leukemia Group B study. Clin Cancer Res. 1997; 3: 19771984.
  • 4
    Kish JA, Wolf M, Crawford ED, et al. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group study. Cancer. 1994; 74: 916919.
  • 5
    Rini BI, Vogelzang NJ, Dumas MC, et al. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol. 2000; 18: 24192426.
  • 6
    Stadler WM. Cytotoxic chemotherapy for metastatic renal cell carcinoma. Urologe A. 2004; 43(Suppl 3): 145146.
  • 7
    Fossa SD. Interferon in metastatic renal cell carcinoma. Semin Oncol. 2000; 27: 187193.
  • 8
    Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004; 22: 454463.
  • 9
    Chow WH, Devesa SS, Warren JL, et al. Rising incidence of renal cell cancer in the United States. JAMA. 1999; 281: 16281631.
  • 10
    Storkel S, Eble JN, Adlakha K et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997; 80: 987989.
  • 11
    Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971; 68: 820823.
  • 12
    Maher ER, Yates JR, Ferguson-Smith MA. Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma. J Med Genet. 1990; 27: 311314.
  • 13
    Brauch H, Weirich G, Brieger J, et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res. 2000; 60: 19421948.
  • 14
    Shuin T, Kondo K, Torigoe S, et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 1994; 54: 28522855.
  • 15
    Yao M, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst. 2002; 94: 15691575.
  • 16
    Kondo K, Yao M, Yoshida M, et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer. 2002; 34: 5868.
  • 17
    Leung SK, Ohh M. Playing tag with HIF: the VHL Story. J Biomed Biotechnol. 2002; 2: 131135.
  • 18
    Knebelmann B, Ananth S, Cohen HT, et al. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res. 1998; 58: 226231.
  • 19
    Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992; 359: 843845.
  • 20
    Izawa JI, Dinney CP. The role of angiogenesis in prostate and other urologic cancers: a review. CMAJ. 2001; 164: 662670.
  • 21
    Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992; 3: 6571.
  • 22
    Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005; 23: 10111027.
  • 23
    Slaton JW, Inoue K, Perrotte P, et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol. 2001; 158: 735743.
  • 24
    Ostman A, Heldin CH. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res. 2001; 80: 138.
  • 25
    Pore N, Liu S, Haas-Kogan DA, et al. PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res. 2003; 63: 236241.
  • 26
    Rak J, Kerbel RS. Ras regulation of vascular endothelial growth factor and angiogenesis. Methods Enzymol. 2001; 333: 267283.
  • 27
    Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie. 2002; 25: 511518.
  • 28
    Oka H, Chatani Y, Hoshino R, et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 1995; 55: 41824187.
  • 29
    Eisenmann KM, VanBrocklin MW, Staffend NA, et al. Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res. 2003; 63: 83308337.
  • 30
    Ley R, Ewings KE, Hadfield K, et al. Extracellular signal-regulated kinases 1/2 are serum-stimulated “Bim(EL) kinases” that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover. J Biol Chem. 2004; 279: 88378847.
  • 31
    Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell. 1996; 87: 629638.
  • 32
    Chen J, Fujii K, Zhang L, et al. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci USA. 2001; 98: 77837788.
  • 33
    Troppmair J, Rapp UR. Raf and the road to cell survival: a tale of bad spells, ring bearers and detours. Biochem Pharmacol. 2003; 66: 13411345.
  • 34
    Alavi A, Hood JD, Frausto R, et al. Role of Raf in vascular protection from distinct apoptotic stimuli. Science. 2003; 301: 9496.
  • 35
    Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002; 22: 70047014.
  • 36
    Mita MM, Mita A, Rowinsky EK. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther. 2003; 2: S169S177.
  • 37
    Brenner W, Farber G, Herget T, et al. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer. 2002; 99: 5357.
  • 38
    Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001; 19: 843850.
  • 39
    Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001; 19: 851856.
  • 40
    Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349: 427434.
  • 41
    Singh RK, Gutman M, Bucana CD, et al. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA. 1995; 92: 45624566.
  • 42
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 23352342.
  • 43
    Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000; 60: 21782189.
  • 44
    George D, Michaelson D, Oh WK. Phase 1 study of PTK787/ZK222584 (PTK/ZK) in metastatic renal cell carcinoma [abstract 1548]. Proc Am Soc Clin Oncol. 2003; 22: 385.
  • 45
    Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol. 2003; 21: 39553964.
  • 46
    Steward WP, Thomas A, Morgan B, et al. Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer [abstract 3556]. Proc Am Assoc Cancer Res. 2004; 45: 259.
  • 47
    Raymond E, Faivre S, Vera K, et al. Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers [abstract 769]. Proc Am Soc Clin Oncol. 2003; 22: 192.
  • 48
    Motzer RJ, Rini BI, Michaelson D, et al. SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma [abstract 4500]. Proc Am Assoc Cancer Res. 2004; 45: 381.
  • 49
    Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64: 70997109.
  • 50
    Strumberg D, Awada A, Piccart P, et al. Final report of the multiple single agent phase I clinical trials of the novel Raf kinase inhibitor BAY 43-9006 in patients with refractory solid tumors [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 203.
  • 51
    Kupsch P, Passarge K, Richly H, et al. Results of a phase I trial of BAY 43-9006 in combination with oxaliplatin in patients with refractory solid tumors [abstract 3056]. Proc Am Assoc Cancer Res. 2004; 23: 209.
  • 52
    Richly H, Kupsch P, Passarge K, et al. Results of a phase I trial of BAY 43-9006 in combination with doxirubicin in patients with refractory solid tumors [abstract 3049]. Proc Am Assoc Cancer Res. 2004; 23: 207.
  • 53
    Siu LL, Awada A, Takimoto CH, et al. A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer [abstract 3059]. Proc Am Soc Clin Oncol. 2004; 23: 209.
  • 54
    Flaherty KT, Brose M, Schuchter L, et al. Phase I/II trial of BAY 43-9006, carboplatin and paclitaxel demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma [abstract]. Proc Am Soc Clin Oncol. 2004; 23: 708.
  • 55
    Ratain MJ, Flaherty KT, Stadler WM, et al. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT) [abstract 4501]. Proc Am Assoc Cancer Res. 2004; 23: 381. See also oral presentation available at URL: http://www.asco.org/ [accessed April 20, 2005].
  • 56
    Bayer and Onyx announce positive phase II data in patients with advanced kidney cancer. Available at URL: http://www.onyx-pharm.com/news/pr_102504.html. 2004 [accessed April 20, 2005].
  • 57
    Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003; 21: 22372246.
  • 58
    Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003; 290: 21492158.
  • 59
    Drucker BJ, Schwartz L, Marion S, et al. Phase II trial of ZD1839 (Iressa), an EGF receptor inhibitor, in patients with advanced renal cell carcinoma [abstract 720]. Proc Am Soc Clin Oncol. 2002; 21: 182.
  • 60
    Beeram M, Rowinsky EK, Weiss GR, et al. A phase II, pharmacokinetic (PK) and biological correlative study of OSI-774 (Tarceva) in patients with advanced renal cell carcinoma, with FDG-PET imaging: evidence of durable stable disease and antitumor activity [abstract 369]. Eur J Cancer Suppl. 2005; 2: 111.
  • 61
    Prewett M, Rothman M, Waksal H, et al. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res. 1998; 4: 29572966.
  • 62
    Motzer RJ, Amato R, Todd M, et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs. 2003; 21: 99101.
  • 63
    Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol. 2002; 29: 4750.
  • 64
    Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol. 2004; 22: 30033015.
  • 65
    Wilhelm S, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum antitumor activity and targets RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64: 70997109.
  • 66
    Wilhelm S, Housley T, Rong H, et al. The novel Raf inhibitor BAY 43-9006 blocks signaling and proliferation in BRAF mutant and wildtype melanoma and colorectal tumor cell lines [abstract 106609]. Proc Am Assoc Cancer Res. 2003; 44: 164.
  • 67
    LoRusso PP, Adjei AA, Meyer MB, et al. A phase I clinical and pharmocokinetic evaluation of the oral MEK inhibitor, CI-1040, administered for 21 consecutive days, repeated every 4 weeks in patients with advanced cancer [abstract 321]. Proc Am Soc Clin Oncol. 2002; 21: 79.
  • 68
    Gibbons JJ, Discafani C, Peterson R. The effect of CCI-779, a novel macrolide anti-tumor agent, on growth of human tumor cells in vitro and in nude mouse xenografts in vivo [abstract 1000]. Proc Am Assoc Cancer Res. 1999; 40: 301.
  • 69
    Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004; 22: 909918.
  • 70
    Smith JW, Ko Y-J, Dutcher J, et al. Update of a phase I study of intravenous CCI-779 given in combination with interferon-alpha to patients with advanced renal cell carcinoma [abstract 4513]. Proc Am Assoc Cancer Res. 2004; 23: 384.
  • 71
    Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res. 2002; 62: 19962003.
  • 72
    Hainsworth J, Sosman J, Spigel DR, et al. Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC) [abstract 4502]. Proc Am Assoc Cancer Res. 2004; 23: 381. See also oral presentation available at URL: http://www.asco.org [accessed April 20, 2005].
  • 73
    Hidalgo M. New target, new drug, old paradigm. J Clin Oncol. 2004; 22: 22702272.